Comparing Tango Therapeutics (NASDAQ:TNGX) & Rosetta Genomics (OTCMKTS:ROSGQ)

Tango Therapeutics (NASDAQ:TNGX) and Rosetta Genomics (OTCMKTS:ROSGQ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Valuation and Earnings

This table compares Tango Therapeutics and Rosetta Genomics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$40.99 million	3.97	-$101.74 million	($1.22)	-1.23
Rosetta Genomics	N/A	N/A	N/A	N/A	N/A

Rosetta Genomics has lower revenue, but higher earnings than Tango Therapeutics.

Analyst Recommendations

This is a breakdown of recent recommendations for Tango Therapeutics and Rosetta Genomics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	0	0	7	0	3.00
Rosetta Genomics	0	0	0	0	0.00

Tango Therapeutics presently has a consensus target price of $12.33, suggesting a potential upside of 722.22%. Given Tango Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Tango Therapeutics is more favorable than Rosetta Genomics.

Profitability

This table compares Tango Therapeutics and Rosetta Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-284.42%	-49.64%	-32.00%
Rosetta Genomics	N/A	N/A	N/A

Institutional & Insider Ownership

79.0% of Tango Therapeutics shares are held by institutional investors. 6.3% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Tango Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of -7.49, indicating that its stock price is 849% less volatile than the S&P 500.

Summary

Tango Therapeutics beats Rosetta Genomics on 7 of the 10 factors compared between the two stocks.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

About Rosetta Genomics

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.